Streetbeat News

Regulatory

KSCP

Knightscope, Inc. (NASDAQ:KSCP) has received Authority to Operate (ATO) from FedRAMP, sponsored by the U.S. Department of Veterans Affairs. This allows Knightscope to be listed on the FedRAMP Marketplace as an approved provider for federal agencies and begin deployment for the VA contract. The company's 2024 Roadmap includes growth, margin improvements, acquisitions, and pre-orders for the new K7 in 2025.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 2:32 pm

AAPL

ADBE

AMZN

GOOG

MSFT

techUK, representing companies like Apple, Google, and Microsoft, opposes UK's proposed surveillance laws, fearing data security threats and legal conflicts. The group, which includes Apple, Alphabet's Google, Microsoft, Adobe, and Amazon, seeks to discuss the Investigatory Powers Act changes that could undermine encryption and impact tech investments in the UK. Apple has previously resisted such laws and threatened to withdraw iMessage and FaceTime over encryption issues.

Portfolio Pulse from Rounak Jain

January 03, 2024 | 2:21 pm

PFE

Health Canada has approved Pfizer Canada's gene therapy BEQVEZ for adults with hemophilia B. The approval is based on the Phase 3 BENEGENE-2 study, which showed potential in reducing the burden of frequent infusions. Over 700 individuals in Canada are affected by hemophilia B. The Canadian Hemophilia Society welcomed the approval and is working to make the therapy accessible across Canada.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 2:14 pm

GOVX

GeoVax Labs, Inc. (NASDAQ:GOVX) has been granted a U.S. patent for a malaria vaccine that covers both prevention and treatment. The patent, No. 11,857,611, is for a vaccine using GeoVax's MVA vector expressing Plasmodium antigens. This vaccine aims to induce an immune response targeting multiple stages of the malaria parasite's life cycle. The issuance of this patent comes as the first cases of locally transmitted malaria have been reported in the U.S. in 20 years. GeoVax's President and CEO, David Dodd, emphasized the company's commitment to public health and the development of vaccines against global threats like malaria.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 2:01 pm

TENX

Trading for TENX was halted and then resumed at 8:55 AM ET, with updated quotation resumption times following the release of news.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 1:55 pm

BNGO

Bionano Laboratories has announced the publication of a framework paper for the clinical adoption of Optical Genome Mapping (OGM) for hematological malignancy applications. The paper, co-authored by an international consortium of 18 cancer researchers, provides recommendations for laboratories on assay development, clinical validation, and more. Bionano's OGM-Dx™ HemeOne is an LDT developed based on this framework.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 1:51 pm

ENTX

Entera Bio has been granted a 180-day extension by the Nasdaq Stock Market to regain compliance with the market's listing requirements.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 1:49 pm

WKHS

Workhorse Group Inc. (NASDAQ:WKHS) announced that its W56 electric vehicle has been approved for the California Air Resources Board's HVIP incentive program, which offers a base voucher of $85,000 per vehicle to reduce cost barriers for EV ownership in California. The W56 is a Class 5/6 model chassis platform, with production starting in September 2023. Workhorse has received its first fleet purchase order for W56 step vans in California and is aiming to expand market share in the EV step van segment.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 1:46 pm

ENVB

Enveric Biosciences has announced EB-003 as its lead drug candidate from the EVM301 series, with plans to start preclinical development in 2024 in preparation for an Investigational New Drug (IND) submission.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 1:43 pm

BTCUSD

Bitcoin's price dropped over 9% after Matrixport released a report predicting the SEC will reject all Bitcoin Spot ETF proposals in January 2024. The report cites the political composition of the SEC and Chair Gary Gensler's cautious stance on crypto as reasons for the likely rejections. The drop caused $500 million in liquidations across derivatives exchanges. Matrixport advises traders to hedge against further declines but maintains a positive long-term outlook for Bitcoin.

Portfolio Pulse from Murtuza Merchant

January 03, 2024 | 1:38 pm